Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31046825 | 0.81 | DGAT1 (0.36) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL28915362 | 0.76 | DGAT1 (0.43) | DGAT1SOAT1GRM5 | |
| SCHEMBL31046828 | 0.75 | DGAT1 (0.49) | DGAT1SOAT1CNR2CNR1 | |
| SCHEMBL1535205 | 0.74 | PRKCI (0.36) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL2179855 | 0.74 | GRM5 (0.39) | GRM5SYKKCNH2 | |
| SCHEMBL18502145 | 0.74 | GRM5 (0.53) | GRM5 | |
| SCHEMBL30509867 | 0.72 | SIRT3 (0.37) | DGAT1SOAT1GRM5SYKZAP70 | |
| SCHEMBL26783151 | 0.72 | PDE10A (0.36) | GRM5PDE10AKDM5B | |
| SCHEMBL3460085 | 0.72 | SIRT3 (0.37) | DGAT1SOAT1GRM5SYKZAP70 | |
| SCHEMBL3825584 | 0.71 | HSD11B1 (0.49) | DGAT1SOAT1SYKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | DGAT1 4804/4885SOAT1 4605/4885GRM5 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.